Update on the use of dutasteride in the management of benign prostatic hypertrophy

Joe Miller, Thomas H TarterDivision of Urology, Southern Illinois University School of Medicine, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joe Miller, Thomas H Tarter
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/0ff1dce861134cfd9c3abd9be8d3c16b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ff1dce861134cfd9c3abd9be8d3c16b
record_format	dspace
spelling	oai:doaj.org-article:0ff1dce861134cfd9c3abd9be8d3c16b2021-12-02T05:03:28ZUpdate on the use of dutasteride in the management of benign prostatic hypertrophy1178-1998https://doaj.org/article/0ff1dce861134cfd9c3abd9be8d3c16b2007-04-01T00:00:00Zhttps://www.dovepress.com/update-on-the-use-of-dutasteride-in-the-management-of-benign-prostatic-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Joe Miller, Thomas H TarterDivision of Urology, Southern Illinois University School of Medicine, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection, and acute urinary retention. Medical treatments of symptomatic BPH include; 1) the 5α-reductase inhibitors, 2) the α1-adrenergic antagonists, and 3) the combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that α1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. The combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist reduces the clinical progression of BPH over either class of drug alone.Keywords: prostatic hyperplasia, 5α-reductase, dutasterideJoe MillerThomas H TarterDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 99-104 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Joe Miller Thomas H Tarter Update on the use of dutasteride in the management of benign prostatic hypertrophy
description	Joe Miller, Thomas H TarterDivision of Urology, Southern Illinois University School of Medicine, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS), urinary tract infection, and acute urinary retention. Medical treatments of symptomatic BPH include; 1) the 5α-reductase inhibitors, 2) the α1-adrenergic antagonists, and 3) the combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that α1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. The combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist reduces the clinical progression of BPH over either class of drug alone.Keywords: prostatic hyperplasia, 5α-reductase, dutasteride
format	article
author	Joe Miller Thomas H Tarter
author_facet	Joe Miller Thomas H Tarter
author_sort	Joe Miller
title	Update on the use of dutasteride in the management of benign prostatic hypertrophy
title_short	Update on the use of dutasteride in the management of benign prostatic hypertrophy
title_full	Update on the use of dutasteride in the management of benign prostatic hypertrophy
title_fullStr	Update on the use of dutasteride in the management of benign prostatic hypertrophy
title_full_unstemmed	Update on the use of dutasteride in the management of benign prostatic hypertrophy
title_sort	update on the use of dutasteride in the management of benign prostatic hypertrophy
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/0ff1dce861134cfd9c3abd9be8d3c16b
work_keys_str_mv	AT joemiller updateontheuseofdutasterideinthemanagementofbenignprostatichypertrophy AT thomashtarter updateontheuseofdutasterideinthemanagementofbenignprostatichypertrophy
_version_	1718400692791541760

Update on the use of dutasteride in the management of benign prostatic hypertrophy

Ejemplares similares